Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TPMT | P51580 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
| ▸ | GFER | P55789 | 1/20 | 0.47 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11598615 | 0.94 | TPMT (0.57) | VCAM1MAPTKDM4EPOLBMAPK1 | |
| SCHEMBL30159180 | 0.92 | MAPT (0.52) | VCAM1MAPTKDM4EPOLBMAPK1 | |
| SCHEMBL22081923 | 0.92 | MAPT (0.52) | VCAM1MAPTKDM4EPOLBMAPK1 | |
| SCHEMBL31016374 | 0.90 | TPMT (0.54) | VCAM1MAPTKDM4EPOLBMAPK1 | |
| SCHEMBL31161445 | 0.90 | LMNA (0.53) | VCAM1MAPTKDM4EPOLBMAPK1 | |
| SCHEMBL10608607 | 0.90 | LMNA (0.53) | VCAM1MAPTKDM4EPOLBMAPK1 | |
| SCHEMBL7573734 | 0.90 | TPMT (0.54) | VCAM1MAPTKDM4EPOLBMAPK1 | |
| SCHEMBL1458078 | 0.89 | VCAM1 (0.49) | VCAM1MAPTKDM4EPOLBMAPK1 | |
| SCHEMBL21681844 | 0.89 | VCAM1 (0.49) | VCAM1MAPTKDM4EPOLBMAPK1 | |
| SCHEMBL15408520 | 0.89 | VCAM1 (0.49) | VCAM1MAPTKDM4EPOLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | Jubilant Epipad LLC | 2025-10-02 | — | — | US | disclosed |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC | 2024-05-16 | — | — | US | disclosed |
| EP-3684767-B1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | Jubilant Epipad LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| CN-116041228-B | Synthesis method of bumetanide | 沈阳希贝康医药科技有限公司 | 2024-03-12 | — | — | CN | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | Jubilant Epipad LLC (US) | 2023-12-05 | — | — | US | disclosed |
| CN-116041228-A | Synthesis method of bumetanide | 沈阳希贝康医药科技有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-111108105-B | Heterocyclic compounds as PAD inhibitors | 朱比兰特埃皮帕德有限公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-3475277-B1 | ANTI-INFECTIVE HETEROCYCLIC COMPOUNDS AND USES THEREOF | BIOIMICS AB (SE) | 2021-10-20 | — | — | EP | disclosed |
| WO-1996029067-A1 | ANTI-VIRAL AND ANTI-CANCER AGENTS | RADOPATH LIMITED (GB) | 1996-09-26 | — | — | WO | disclosed |
| EP-0700287-A1 | ARYLATING MEDICAMENTS | RADOPATH LIMITED (GB) | 1996-03-13 | — | — | EP | disclosed |
| EP-0677292-A1 | Anti-viral and anti-cancer agents | RADOPATH LIMITED (GB) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995024897-A1 | ANTI-VIRAL AND ANTI-CANCER AGENTS | RADOPATH LIMITED (GB) | 1995-09-21 | — | — | WO | disclosed |
| WO-1994027584-A2 | ARYLATING MEDICAMENTS | RADOPATH LIMITED (GB) | 1994-12-08 | — | — | WO | disclosed |
| US-4806151-A | ESTERIFICATION, THEN AMINATION OF 4-CHLORO-3,5-DINITRO-BENZOIC ACID; ACID CATALYST, SALT FORMATION OF EXCESS; FUNGICIDES, HERBICIDES | BUDAPESTI VEGYIMUVEK (HU) | 1989-02-21 | — | — | US | disclosed |
| US-4186127-A | ANTIALLERGENS | THE UPJOHN COMPANY (US) | 1980-01-29 | — | — | US | disclosed |
| US-4159278-A | PROPHYAXIS, ANTIALLERGENS, SENSITIZATION | THE UPJOHN COMPANY (US) | 1979-06-26 | — | — | US | disclosed |
| US-4089973-A | Cyano phenylene dioxamic acid compounds used in the treatment of allergy | THE UPJOHN COMPANY (US) | 1978-05-16 | — | — | US | disclosed |
| US-3993679-A | ANTIALLERGY | THE UPJOHN COMPANY (US) | 1976-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11833156-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | VCAM1 686/4885MAPT 3841/4885KDM4E 1347/4885 |
| US-20250302842-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATMENT OF CANCERS | NES, VHL, ETV6 | VCAM1 1423/4885MAPT 2514/4885KDM4E 2928/4885 |
| US-20240156831-A1 | HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS | PADI4, PADI2, PADI1 | VCAM1 793/4885MAPT 4416/4885KDM4E 341/4885 |
| US-12357639-B2 | Heterocyclic compounds as pad inhibitors | PADI4, PADI2, PADI1 | VCAM1 793/4885MAPT 4416/4885KDM4E 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.